Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer.

被引：1
|
作者：
Bikkasani, Krishna
Qin, Qian
Lin, Justin
Galsky, Matt D.
Liaw, Bobby Chi-Hung
Oh, William K.
Tsao, Che-Kai
机构：
[1] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY 10029 USA
[2] CUNY, Sch Med, New York, NY 10031 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.184
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
184
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Rucaparib in castration-resistant, metastatic prostate cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2024, 55 (02) : 96 - 98
  • [32] Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials
    Grayling, Michael J.
    McMenamin, Martina
    Chandler, Robert
    Heer, Rakesh
    Wason, James M. S.
    BMC CANCER, 2022, 22 (01)
  • [33] SPOP mutation as a predictive marker for treatment of metastatic castration-resistant prostate cancer.
    Stangl, Andrew
    Willner, Christopher
    Maahs, Lucas
    Burmeister, Charlotte
    Hwang, Clara
    Pilling, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [34] Metastatic castration-resistant prostate cancer. Position paper for structured therapy monitoring
    Miller, K.
    Albers, P.
    Eichenauer, R.
    Geiges, G.
    Grimm, M. -O.
    Koenig, F.
    Mickisch, G.
    Pfister, D.
    Schwentner, C.
    Suttmann, H.
    Zastrow, S.
    UROLOGE, 2014, 53 (05): : 710 - 714
  • [35] Salvage chemotherapy with cisplatin, ifosfamide, and paclitaxel in metastatic castration-resistant prostate cancer.
    Von Amsberg, Gunhild
    Zilles, Mirjam
    Gild, Philipp
    Alsdorf, Winfried
    Boeckelmann, Lukas
    Langebrake, Claudia
    Oh-Hohenhorst, Su Jung
    Tilki, Derya
    Graefen, Markus
    Dyshlovoy, Sergey
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [36] Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
    Lin, Ting-Ting
    Chen, Ye-Hui
    Wu, Yu-Peng
    Chen, Shao-Zhan
    Li, Xiao-Dong
    Lin, Yun-Zhi
    Chen, Shao-Hao
    Zheng, Qing-Shui
    Wei, Yong
    Xu, Ning
    Xue, Xue-Yi
    JOURNAL OF CANCER, 2019, 10 (22): : 5608 - 5613
  • [37] A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.
    Bryce, Alan Haruo
    Karp, Daniel D.
    Tagawa, Scott T.
    Nordquist, Luke T.
    Rathkopf, Dana E.
    Adra, Nabil
    Dorff, Tanya B.
    Baeck, Johan
    O'Donnell, Joseph Francis
    Ames, Tyler David
    Yim, Christina Y.
    Price, Matthew
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [38] PSA surge in patients with castration-resistant prostate cancer receiving docetaxel.
    Tabata, Ken-ichi
    Satoh, Takefumi
    Matsumoto, Kazumasa
    Fujita, Tetsuo
    Iwamura, Masatsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
    Yuji Hakozaki
    Yuta Yamada
    Yuta Takeshima
    Satoru Taguchi
    Taketo Kawai
    Masaki Nakamura
    Takuya Iwaki
    Taro Teshima
    Yoshitaka Kinoshita
    Yoshiyuki Akiyama
    Yusuke Sato
    Daisuke Yamada
    Motofumi Suzuki
    Haruki Kume
    Scientific Reports, 13
  • [40] Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
    Hakozaki, Yuji
    Yamada, Yuta
    Takeshima, Yuta
    Taguchi, Satoru
    Kawai, Taketo
    Nakamura, Masaki
    Iwaki, Takuya
    Teshima, Taro
    Kinoshita, Yoshitaka
    Akiyama, Yoshiyuki
    Sato, Yusuke
    Yamada, Daisuke
    Suzuki, Motofumi
    Kume, Haruki
    SCIENTIFIC REPORTS, 2023, 13 (01)
12345